Načítá se...
Will availability of inhaled human insulin (Exubera(®)) improve management of type 2 diabetes? The design of the Real World trial
BACKGROUND: Common deterrents to insulin therapy for both physicians and patients are the complexity and burden of daily injections. In January 2006, the first inhaled human insulin (INH, Exubera(® )(insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diab...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2006
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1564148/ https://ncbi.nlm.nih.gov/pubmed/16901335 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-7-25 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|